Allogeneic T-cell therapies: from R&D lab to production facility

Cell & Gene Therapy Insights 2021; 7(5), 651–654

10.18609/cgti.2021.088

Published: 9 June 2021
Viewpoint
Jakob Dupont, M.D., Joe Newell

The allogeneic cell therapy field is exploding, with T cells attracting particular attention. While autologous T-cell therapies have been life-changing for many patients, allogeneic platforms hold the promise of “off-the-shelf” cells manufactured at scale and delivered to the patient within days.